Crossject : Focus on regulatory advances and funding requirements in the short term
>Short-term financing requirement - Crossject reported its 2023 figures yesterday. Operating income rose by 32% to € 12.8m, thanks to an increase in R&D expense billed to BARDA (€ 6.7m vs € 1.8m in 2022), while operating expense was relatively flat at € 25.1m, for an operating loss of -€ 12.3m.Cash at end-2023 stood at € 2.3m, but this does not include the initial tranche of € 7m of financing obtained from Heights Capital. The group’s cash position will allow it...Crossject SA is a France-based company that designs and develops medical injection systems. The Company specializes in needle-free, pre-filled, single-use injection systems for intradermal, subcutaneous and intramuscular applications for pharmaceutical companies. Is also has a pipeline and three drugs in the preclinical or clinical phase of research. The Company's products, which are based on well-known injectable drugs (chemicals and biologics), are designed to enhance patients' safety, compliance and comfort. Crossject's first ZENEO SUPERGENERIC product is expected to reach the market in the year 2015. The Company has industrial partnerships with Hirtenberger and Recipharm.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.